corrigenda
Annals of Oncology 26: 2505, 2015 doi:10.1093/annonc/mdv477 Published online 21 October 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer B. H. O’Neil1, A. J. Scott2, W. W. Ma3, S. J. Cohen4, L. Leichman5, D. L. Aisner2, A. R. Menter6, M. A. Tejani7, J. K. Cho8, J. Granfortuna9, L. Coveler10, O. O. Olowokure11, J. C. Baranda12, M. Cusnir13, P. Phillip14, J. Boles15, R. Nazemzadeh16, M. Rarick17, D. J. Cohen18, J. Radford19, L. Fehrenbacher20, R. Bajaj21, V. Bathini22, P. Fanta23, J. Berlin24, A. J. McRee25, R. Maguire26, F. Wilhelm26, M. Maniar26, A. Jimeno2, C. L. Gomes27 & W. A. Messersmith2
Ann Oncol 2015; 26: 1923–1929 (doi: 10.1093/annonc/ mdv264) In the original article, author L. Leichman was omitted.
The corrected authors and affiliations are as above.
Annals of Oncology 26: 2505–2506, 2015 doi:10.1093/annonc/mdv478 Published online 13 October 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) S. Gourgou-Bourgade, D. Cameron, P. Poortmans, B. Asselain, D. Azria, F. Cardoso, R. A’Hern, J. Bliss, J. Bogaerts, H. Bonnefoi, E. Brain, M. J. Cardoso, B. Chibaudel, R. Coleman, T. Cufer, L. Dal Lago, F. Dalenc, E. De Azambuja, M. Debled, S. Delaloge, T. Filleron, J. Gligorov, M. Gutowski, W. Jacot, C. Kirkove, G. MacGrogan, S. Michiels, I. Negreiros, B. V. Offersen, F. Penault Llorca, G. Pruneri, H. Roche, N. S. Russell, F. Schmitt, V. Servent, B. Thürlimann, M. Untch, J. A. van der Hage, G. van Tienhoven, H. Wildiers, J. Yarnold, F. Bonnetain, S. Mathoulin-Pélissier, C. Bellera & T. S. Dabakuyo-Yonli Ann Oncol 2015; 26: 873–879 (doi: 10.1093/annonc/mdv106) In the original manuscript, there were inconsistencies in Table 2.
The corrected Table 2 is below.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
corrigenda
1 Simon Cancer Center, Indiana University School of Medicine, Indianapolis; 2University of Colorado, Denver, Aurora; 3Roswell Park Cancer Institute, Buffalo; 4Fox Chase Cancer Center, Philadelphia; 5New York University, New York; 6Kaiser Permanente, Lone Tree; 7University of Rochester Medical Center, Rochester; 8Oncare Hawaii, Honolulu; 9Cone Health Cancer Center, Greensboro; 10University of Washington, Seattle; 11University of Cincinnati Cancer Institute, Cincinnati; 12University of Kansas Medical Center, Westwood; 13Mount Sinai Medical Center, Miami Beach; 14Karmanos Cancer Institute, Detroit; 15Rex Cancer Center UNC Healthcare, Raleigh; 16Carolinas Health Care, Charlotte; 17Kaiser Permanante Northwest, Portland; 18NYU Clinical Cancer Center, New York; 19Hendersonville Hematology and Oncology at Pardee, Hendersonville; 20Kaiser Permanante Medical Center, Vallejo; 21McLeod Regional Medical Center, Florence; 22University of Massachusetts Memorial, Worcester; 23UCSD Moores Cancer Center, La Jolla; 24Vanderbilt-Ingram Cancer Center, Nashville; 25UNC Lineberger Comprehensive Cancer Center, Chapel Hill; 26Onconova Therapeutics Inc., Newtown; 27Oncology Consortia of Criterium Inc., Saratoga Springs, USA
Annals of Oncology 26: 2505, 2015 doi:10.1093/annonc/mdv477 Published online 21 October 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer B. H. O’Neil1, A. J. Scott2, W. W. Ma3, S. J. Cohen4, L. Leichman5, D. L. Aisner2, A. R. Menter6, M. A. Tejani7, J. K. Cho8, J. Granfortuna9, L. Coveler10, O. O. Olowokure11, J. C. Baranda12, M. Cusnir13, P. Phillip14, J. Boles15, R. Nazemzadeh16, M. Rarick17, D. J. Cohen18, J. Radford19, L. Fehrenbacher20, R. Bajaj21, V. Bathini22, P. Fanta23, J. Berlin24, A. J. McRee25, R. Maguire26, F. Wilhelm26, M. Maniar26, A. Jimeno2, C. L. Gomes27 & W. A. Messersmith2
Ann Oncol 2015; 26: 1923–1929 (doi: 10.1093/annonc/ mdv264) In the original article, author L. Leichman was omitted.
The corrected authors and affiliations are as above.
Annals of Oncology 26: 2505–2506, 2015 doi:10.1093/annonc/mdv478 Published online 13 October 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) S. Gourgou-Bourgade, D. Cameron, P. Poortmans, B. Asselain, D. Azria, F. Cardoso, R. A’Hern, J. Bliss, J. Bogaerts, H. Bonnefoi, E. Brain, M. J. Cardoso, B. Chibaudel, R. Coleman, T. Cufer, L. Dal Lago, F. Dalenc, E. De Azambuja, M. Debled, S. Delaloge, T. Filleron, J. Gligorov, M. Gutowski, W. Jacot, C. Kirkove, G. MacGrogan, S. Michiels, I. Negreiros, B. V. Offersen, F. Penault Llorca, G. Pruneri, H. Roche, N. S. Russell, F. Schmitt, V. Servent, B. Thürlimann, M. Untch, J. A. van der Hage, G. van Tienhoven, H. Wildiers, J. Yarnold, F. Bonnetain, S. Mathoulin-Pélissier, C. Bellera & T. S. Dabakuyo-Yonli Ann Oncol 2015; 26: 873–879 (doi: 10.1093/annonc/mdv106) In the original manuscript, there were inconsistencies in Table 2.
The corrected Table 2 is below.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
corrigenda
1 Simon Cancer Center, Indiana University School of Medicine, Indianapolis; 2University of Colorado, Denver, Aurora; 3Roswell Park Cancer Institute, Buffalo; 4Fox Chase Cancer Center, Philadelphia; 5New York University, New York; 6Kaiser Permanente, Lone Tree; 7University of Rochester Medical Center, Rochester; 8Oncare Hawaii, Honolulu; 9Cone Health Cancer Center, Greensboro; 10University of Washington, Seattle; 11University of Cincinnati Cancer Institute, Cincinnati; 12University of Kansas Medical Center, Westwood; 13Mount Sinai Medical Center, Miami Beach; 14Karmanos Cancer Institute, Detroit; 15Rex Cancer Center UNC Healthcare, Raleigh; 16Carolinas Health Care, Charlotte; 17Kaiser Permanante Northwest, Portland; 18NYU Clinical Cancer Center, New York; 19Hendersonville Hematology and Oncology at Pardee, Hendersonville; 20Kaiser Permanante Medical Center, Vallejo; 21McLeod Regional Medical Center, Florence; 22University of Massachusetts Memorial, Worcester; 23UCSD Moores Cancer Center, La Jolla; 24Vanderbilt-Ingram Cancer Center, Nashville; 25UNC Lineberger Comprehensive Cancer Center, Chapel Hill; 26Onconova Therapeutics Inc., Newtown; 27Oncology Consortia of Criterium Inc., Saratoga Springs, USA
